Masimo Opioid Halo, an opioid overdose prevention and alert system, will be made available over the counter.

IRVINE, California—Masimo announced that Masimo Opioid Halo, an opioid overdose prevention and alert system, has been granted a De Novo by the FDA, making it the first and only FDA-cleared monitoring solution for detecting opioid-induced respiratory depression, the leading cause of death from opioid overdose. With the De Novo, Masimo also becomes the first winner of an FDA Opioid Innovation Challenge to have an authorized solution designed to help solve the U.S. opioid crisis.

WASHINGTON, D.C. (June 4, 2018)—The Centers for Medicare & Medicaid Services (CMS) released the first ever Medicaid and Children’s Health Insurance Program (CHIP) Scorecard, a central component of the Administration’s commitment to modernize the Medicaid and CHIP program through greater transparency and accountability for the program’s outcomes.  For the first time, CMS published state Medicaid and CHIP quality metrics along with federally reported measures in a Scorecard format. 

The proposed rule eliminates administrative hurdles to providing more affordable prescription drugs and will allow Medicare to combat opioid overprescribing and abuse.

WASHINGTON, D.C. (November 20, 2017)—The Centers for Medicare & Medicaid Services (CMS) issued a proposed rule November 16, that includes a number of changes that, if finalized, will ensure that Part D Medicare enrollees have access to more affordable prescription drugs and more robust prescription drug coverage at the pharmacy they prefer. The rule also gives health plans a new tool to combat the opioid crisis.